English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Expanded Phase II Trials by Chi-Med Triggers US$10 Million Milestone from AstraZeneca

Jun. 20, 2016

June 20, 2016. Hutchison China MediTech Limited (“Chi-Med”) has announced the initiation of a Phase II expansion of the ongoing TATTON trial to evaluate the selective c-Met inhibitor savolitinib (AZD6094) in epidermal growth factor receptor (“EGFR”) mutant non-small cell lung cancer (“NSCLC”) patients. Savolitinib has the potential to address major unmet medical needs in c-Met-driven subsets of NSCLC, a disease that is estimated to afflict approximately 1.7 million new patients annually worldwide.

The initiation of the expanded Phase II study has triggered a US$10 million milestone payment to Hutchison MediPharma Limited (“HMP”) (a 99.8% held subsidiary of Chi-Med) under the terms of the agreement with AstraZeneca PLC (“AstraZeneca”) signed in December 2011.